title: Adiponectin downregulates galectin-3 whose cellular form is elevated whereas its soluble form is reduced in type 2 diabetic monocytes.
abstract: Galectin-3 plays a role in atherosclerotic diseases, and the effect of adiponectin that protects from atherosclerotic diseases on monocytic galectin-3 was analysed. Adiponectin reduced galectin-3 mRNA, its cellular and soluble form, and this effect was impaired in T2D cells. Cellular galectin-3 was higher in monocytes of overweight than normal-weight donors and was highest in T2D cells. Cellular galectin-3 positively correlated with the BMI of the donors and negatively with soluble monocyte galectin-3. Circulating levels of total adiponectin did not correlate with cellular or soluble galectin-3 indicating that additional factors contribute to higher cellular monocytic galectin-3 in obesity and T2D.
authors.affiliation: Department of Internal Medicine I, Regensburg University Hospital, D-93042 Regensburg, Germany.
authors.forename: Markus
authors.initials: M
authors.lastname: Weber
authors.forename: Daniela
authors.initials: D
authors.lastname: Sporrer
authors.forename: Johanna
authors.initials: J
authors.lastname: Weigert
authors.forename: Josef
authors.initials: J
authors.lastname: Wanninger
authors.forename: Markus
authors.initials: M
authors.lastname: Neumeier
authors.forename: Sylvia
authors.initials: S
authors.lastname: Wurm
authors.forename: Fabian
authors.initials: F
authors.lastname: Stögbauer
authors.forename: Andrea
authors.initials: A
authors.lastname: Kopp
authors.forename: Margarita
authors.initials: M
authors.lastname: Bala
authors.forename: Andreas
authors.initials: A
authors.lastname: Schäffler
authors.forename: Christa
authors.initials: C
authors.lastname: Buechler
mesh_terms: D052242:Adiponectin / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives / Q000494:pharmacology; D015992:Body Mass Index; D002478:Cells, Cultured; D002784:Cholesterol / Q000378:metabolism; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004797:Enzyme-Linked Immunosorbent Assay; D037502:Galectin 3 / Q000737:chemistry / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D015151:Immunoblotting; D008297:Male; D008687:Metformin / Q000494:pharmacology; D008875:Middle Aged; D009000:Monocytes / Q000166:cytology / Q000187:drug effects* / Q000378:metabolism; D019301:Oleic Acid / Q000494:pharmacology; D019308:Palmitic Acid / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012265:Ribonucleotides / Q000494:pharmacology; D012995:Solubility; D013997:Time Factors
chemical_list: D052242:Adiponectin; D037502:Galectin 3; D011720:Pyrazoles; D011743:Pyrimidines; D012265:Ribonucleotides; C516138:dorsomorphin; D019301:Oleic Acid; D019308:Palmitic Acid; D000620:Aminoimidazole Carboxamide; D008687:Metformin; D002784:Cholesterol; C031143:AICA ribonucleotide